Abbott and Enanta Announce Advancement of Hepatitis C Collaboration

WATERTOWN, Mass., March 2 /PRNewswire/ -- Enanta Pharmaceuticals, Inc. announced today the nomination of lead development candidate, EDP-239, from its NS5A hepatitis C virus (HCV) inhibitor program. EDP-239 has demonstrated picomolar potency against multiple genotypes of the virus and a preclinical pharmacokinetic profile amenable to once-a-day...

CombinatoRx scores $40M payout on FDA approval

CombinatoRx's complex merger deal with Neuromed will pay off with a $40 million milestone earned with today's announcement that the FDA has approved Exalgo, a once-daily pain therapy. Covidien, which partnered on the program, will handle the commercial rollout and fork over the...

National Cancer Institute awards PDS Biotechnology $1.28M phase 2 SBIR contract

PDS Biotechnology Corporation today announced that the company has been awarded a $1.28M phase 2 SBIR contract by the National Cancer Institute division of the US National Institutes of Health. The contract provides funding to complete studies required to file an Investigational New Drug Application (IND) with the FDA for the company's lead human papillomavirus (HPV)-cancer product late in...

Bioniche Achieves Two Additional Milestones Under Licensing Agreement; Endo Takes up Global Rights

BELLEVILLE, ON, Feb. 12 /PRNewswire-FirstCall/ - Bioniche Life Sciences Inc. (TSX: BNC), a research-based, technology driven Canadian biopharmaceutical company, today announced that it has met the obligations associated with two milestones under its licensing agreement with Endo Pharmaceuticals ( ENDP) for exclusive rights to develop and market Bioniche's proprietary product for non-muscle-invasive bladder cancer in North America. The achievement of these milestones triggers a total payment of...

Catalysis Foundation for Health Receives $5 Million Grant for Tuberculosis Diagnostic Biomarker Research

EMERYVILLE, Calif., Feb. 10 /PRNewswire/ -- The Catalysis Foundation for Health (Catalysis), a 501 (c) (3) non-profit entity dedicated to developing sustainable diagnostics for the developing world, announced today that it has received a $5 million grant from the Bill & Melinda Gates...

Abbott and Pierre Fabre SA Announce Collaboration to Research and Develop Novel Treatments for Cancer

Monoclonal Antibody Adds Early-Stage Biologic to Abbott's Oncology Pipeline ABBOTT PARK, Ill. and CASTRES, France, Feb. 1 /PRNewswire-FirstCall/ -- Abbott (NYSE: ABT) announced today an exclusive worldwide licensing agreement with Pierre Fabre SA to develop and commercialize h224G11, a pre-clinical monoclonal antibody identified at the Centre d'Immunologie Pierre Fabre (CIPF) in France and targeting the cMet receptor for the treatment of cancer. cMet protein plays a role in the progression of...

Neovasc completes first tranche of $1.329 million non-brokered private placement

--Proceeds will be Used to Fund Reducer(TM) COSIRA Multi-Center Clinical Trial-- VANCOUVER, Jan. 28 /PRNewswire-FirstCall/ - Neovasc Inc. (TSXV: NVC) today announced that it has completed the first tranche of a previously announced non-brokered private placement of approximately 7.4 million units at the price of $0.27per unit for aggregate gross proceeds of up to $2.0 million. The proceeds of the offering will be used primarily to fund the COSIRA trial - a multi-center clinical trial...

Venture capital investments decline in 4th qtr

(AP) -- Venture capitalists invested less money in U.S. startups in the fourth quarter and showed signs of spreading out those fewer dollars among more companies, reflecting continued caution amid uncertainty about the...

Indian biotech exec predicts a $10B industry boom

One of the leading figures in India's biotech industry says that the field is positioned to more than double in size over the next five years as more companies in the subcontinent tap in on the potential for opportunities in clinical trials, manufacturing and more. And she adds that India is well positioned to profit from the shift in R&D and trial work from Europe and the U.S. to...

Georgia officials map out Atlanta R&D complex

Economic development officials in Georgia are hoping to trigger something of a biotech boom in southwest Atlanta with the creation of a 170-acre research park in the redeveloped Fort McPherson. The park could be anchored by a research center and marketed as an R&D complex for "vaccine development, regenerative medicine, cardiovascular research, and neuroscience," according to the Atlanta Business Chronicle. And a fully developed complex could lure 7,000 biotech...